1. Detection of fucosylated haptoglobin using the 10-7G antibody as a biomarker for evaluating endoscopic remission in ulcerative colitis.
   Motooka K, Morishita K, Ito N, Shinzaki S, Tashiro T, Nojima S, Shimizu K, Date M, Sakata N, Yamada M, Takamatsu S, Kamada Y, Iijima H, Mizushima T, Morii E, Takehara T, Miyoshi E.
   World J Gastroenterol. 2021 Jan 14;27(2):162-175.
2. Rebleeding in patients with delayed bleeding after endoscopic submucosal dissection for early gastric cancer.
   Hashimoto M, Hatta W, Tsuji Y, Yoshio T, Yabuuchi Y, Hoteya S, Doyama H, Nagami Y, Hikichi T, Kobayashi M, Morita Y, Sumiyoshi T, Iguchi M, Tomida H, Inoue T, Mikami T, Hasatani K, Nishikawa J, Matsumura T, Nebiki H, Nakamatsu D, Ohnita K, Suzuki H, Ueyama H, Hayashi Y, Sugimoto M, Fujishiro M, Masamune A, Ohira H; Collaborators.
   Dig Endosc. 2021 Feb 4.
3. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
   Myojin Y, Kodama T, Maesaka K, Motooka D, Sato Y, Tanaka S, Abe Y, Ohkawa K, Mita E, Hayashi Y, Hikita H, Sakamori R, Tatsumi T, Taguchi A, Eguchi H, Takehara T.
   Clin Cancer Res. 2021 Feb 15;27(4):1150-1161.
4. Persistent hepatocyte apoptosis promotes tumorigenesis from diethylnitrosamine-transformed hepatocytes through increased oxidative stress, independent of compensatory liver regeneration.
   Nozaki Y, Hikita H, Tanaka S, Fukumoto K, Urabe M, Sato K, Myojin Y, Doi A, Murai K, Sakane S, Saito Y, Kodama T, Sakamori R, Tatsumi T, Takehara T.
   Sci Rep. 2021 Feb 9;11(1):3363.
5. Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study.
   Qi X, Liu Y, Wang J, Fallowfield JA, Wang J, Li X, Shi J, Pan H, Zou S, Zhang H, Chen Z, Li F, Luo Y, Mei M, Liu H, Wang Z, Li J, Yang H, Xiang H, Li X, Liu T, Zheng MH, Liu C, Huang Y, Xu D, Li X, Kang N, He Q, Gu Y, Zhang G, Shao C, Liu D, Zhang L, Li X, Kawada N, Jiang Z, Wang F, Xiong B, Takehara T, Rockey DC; COVID-Cirrhosis-CHESS Group.
   Gut. 2021 Feb;70(2):433-436.
6. Hepatic Stellate Cells in Hepatocellular Carcinoma Promote Tumor Growth Via Growth Differentiation Factor 15 Production.
   Myojin Y, Hikita H, Sugiyama M, Sasaki Y, Fukumoto K, Sakane S, Makino Y, Takemura N, Yamada R, Shigekawa M, Kodama T, Sakamori R, Kobayashi S, Tatsumi T, Suemizu H, Eguchi H, Kokudo N, Mizokami M, Takehara T.
   Gastroenterology. 2021 Apr;160(5):1741-1754.e16.
7. Efficacy of Ramucirumab Versus Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma.
   Maesaka K, Sakamori R, Yamada R, Tahata Y, Ohkawa K, Oshita M, Tamura S, Hagiwara H, Mita E, Yakushijin T, Inada M, Kodama T, Hikita H, Tatsumi T, Takehara T.
   Anticancer Res. 2021 Apr;41(4):2187-2192.
8. Clinical course of hepatitis C virus-positive patients with decompensated liver cirrhosis in the era of direct-acting antiviral treatment.
   Maesaka K, Sakamori R, Yamada R, Tahata Y, Oshita M, Hagiwara H, Sakakibara M, Tamura S, Hiramatsu N, Inada M, Iio S, Ito T, Yakushijin T, Doi Y, Kodama T, Hikita H, Tatsumi T, Takehara T.
   Hepatol Res. 2021 May;51(5):517-527.
9. Gab1 in livers with persistent hepatocyte apoptosis has an antiapoptotic effect and reduces chronic liver injury, fibrosis, and tumorigenesis.
   Mizutani N, Hikita H, Saito Y, Myojin Y, Sato K, Urabe M, Kurahashi T, Shiode Y, Sakane S, Murai K, Nozaki Y, Kodama T, Sakamori R, Yoshida Y, Tatsumi T, Takehara T.
   Am J Physiol Gastrointest Liver Physiol. 2021 Jun 1;320(6): G958-G968.
10. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study.
    Shinzaki S, Matsuoka K, Tanaka H, Takeshima F, Kato S, Torisu T, Ohta Y, Watanabe K, Nakamura S, Yoshimura N, Kobayashi T, Shiotani A, Hirai F, Hiraoka S, Watanabe M, Matsuura M, Nishimoto S, Mizuno S, Iijima H, Takehara T, Naka T, Kanai T, Matsumoto T.
    J Gastroenterol. 2021 Jun;56(6):560-569.
11. Hepatitis C virus modulates signal peptide peptidase to alter host protein processing.
    Hirano J, Yoshio S, Sakai Y, Songling L, Suzuki T, Itoh Y, Zhang H, Chen DV, Haga S, Oomori H, Kodama T, Maeda Y, Ono Y, Takahashi Y, Standley DM, Yamamoto M, Moriishi K, Moriya K, Kanto T, Takehara T, Koike K, Matsuura Y, Okamoto T.
    Proc Natl Acad Sci U S A. 2021 Jun 1;118(22): e2026184118.
12. Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.
    Kozumi K, Kodama T, Murai H, Sakane S, Govaere O, Cockell S, Motooka D, Kakita N, Yamada Y, Kondo Y, Tahata Y, Yamada R, Hikita H, Sakamori R, Kamada Y, Daly AK, Anstee QM, Tatsumi T, Morii E, Takehara T.
    Hepatology. 2021 Jun 9. Online ahead of print.
13. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.
    Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T.
    Liver Cancer. 2021 Jun;10(3):181-223.
14. Dysregulation of PI3K and Hippo signaling pathways synergistically induces chronic pancreatitis via CTGF upregulation.
    Tamura T, Kodama T, Sato K, Murai K, Yoshioka T, Shigekawa M, Yamada R, Hikita H, Sakamori R, Akita H, Eguchi H, Johnson RL, Yokoi H, Mukoyama M, Tatsumi T, Takehara T.
    J Clin Invest. 2021 Jul 1;131(13): e143414.
15. Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis.
    Yoshihara T, Shinzaki S, Amano T, Iijima H, Takehara T, Inoue N, Uchino M, Esaki M, Kobayashi T, Saruta M, Sugimoto K, Nakamura S, Hata K, Hirai F, Hiraoka S, Fujii T, Matsuura M, Matsuoka K, Watanabe K, Nakase H, Watanabe M.
    J Gastroenterol Hepatol. 2021 Jul;36(7):1744-1753.
16. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.
    Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K.
    J Gastroenterol. 2021 Jul;56(7):593-619.
17. Evidence-based clinical practice guidelines for liver cirrhosis 2020.
    Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K.
    Hepatol Res. 2021 Jul;51(7):725-749.
18. Geriatric nutritional risk index as a prognostic indicator in elderly patients with early colorectal cancer undergoing endoscopic submucosal dissection.
    Kato M, Hayashi Y, Fukuda H, Yamaguchi S, Inoue T, Ogiyama H, Kitamura S, Komori M, Yamamoto K, Yamamoto M, Nagai K, Nakahara M, Egawa S, Yamada T, Sasakawa A, Kizu T, Nishiyama O, Shichijo S, Yoshii S, Tsujii Y, Shinzaki S, Iijima H, Takehara T.
    Dig Endosc. 2021 Jul 23.　Online ahead of print.
19. White Adipose Tissue Autophagy and Adipose-Liver Crosstalk Exacerbate Nonalcoholic Fatty Liver Disease in Mice.
    Sakane S, Hikita H, Shirai K, Myojin Y, Sasaki Y, Kudo S, Fukumoto K, Mizutani N, Tahata Y, Makino Y, Yamada R, Kodama T, Sakamori R, Tatsumi T, Takehara T.
    Cell Mol Gastroenterol Hepatol. 2021 Jul 22: S2352-345X (21)00153-3. Online ahead of print.
20. Helicobacter pylori eradication prevents secondary gastric cancer in patients with mild-to-moderate atrophic gastritis.
    Kato M, Hayashi Y, Nishida T, Oshita M, Nakanishi F, Yamaguchi S, Kitamura S, Nishihara A, Akasaka T, Ogiyama H, Nakahara M, Yamada T, Kishida O, Yamamoto M, Shimayoshi A, Tsujii Y, Kato M, Shinzaki S, Iijima H, Takehara T.
    J Gastroenterol Hepatol. 2021 Aug;36(8):2083-2090.
21. The First Case of Coil Embolization for Left Gastric Vein Aneurysm with Liver Cirrhosis: A Case Report and Review of the Literature.
    Kato S, Sakamori R, Yamada R, Murai K, Yoshioka T, Tahata Y, Shigekawa M, Kodama T, Hikita H, Hongyo H, Ono Y, Higashihara H, Tatsumi T, Takehara T.
    Intern Med. 2021 Aug 15;60(16):2617-2622.
22. Use of a convolutional neural network for classifying microvessels of superficial esophageal squamous cell carcinomas.
    Uema R, Hayashi Y, Tashiro T, Saiki H, Kato M, Amano T, Tani M, Yoshihara T, Inoue T, Kimura K, Iwatani S, Sakatani A, Yoshii S, Tsujii Y, Shinzaki S, Iijima H, Takehara T.
    J Gastroenterol Hepatol. 2021 Aug;36(8):2239-2246.
23. Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma.
    Amano T, Iijima H, Shinzaki S, Tashiro T, Iwatani S, Tani M, Otake Y, Yoshihara T, Sugimoto A, Egawa S, Yamaguchi S, Kinoshita K, Araki M, Hirao M, Sakakibara Y, Hiyama S, Ogawa H, Nagaike K, Murata J, Komori M, Okuda Y, Kizu T, Tsujii Y, Hayashi Y, Inoue T, Takahashi H, Mizushima T, Morii E, Takehara T.
    BMC Cancer. 2021 Aug 31;21(1):978.
24. The First Transileocolic Obliteration for Refractory Esophageal Varices: A Case Report and Review of the Literature.
    Fujii Y, Sakamori R, Yamada R, Yoshioka T, Kodama T, Shigekawa M, Hikita H, Tanaka S, Ishida H, Mita E, Hongyo H, Higashihara H, Noda T, Eguchi H, Tatsumi T, Takehara T.
    Intern Med. 2021 Aug 31. Online ahead of print.
25. Capsid Allosteric Modulators Enhance the Innate Immune Response in Hepatitis B Virus-Infected Hepatocytes During Interferon Administration.
    Fukutomi K, Hikita H, Murai K, Nakabori T, Shimoda A, Fukuoka M, Yamai T, Higuchi Y, Miyakawa K, Suemizu H, Ryo A, Yamada R, Kodama T, Sakamori R, Tatsumi T, Takehara T.
    Hepatol Commun. 2021 Aug 25. Online ahead of print.
26. Suppression of autophagy promotes fibroblast activation in p53-deficient colorectal cancer cells.
    Inoue T, Hayashi Y, Tsujii Y, Yoshii S, Sakatani A, Kimura K, Uema R, Kato M, Saiki H, Shinzaki S, Iijima H, Takehara T.
    Sci Rep. 2021 Sep 30;11(1):19524.
27. Activation of p53 After Irradiation Impairs the Regenerative Capacity of the Mouse Liver.
    Urabe M, Hikita H, Saito Y, Kudo S, Fukumoto K, Mizutani N, Myojin Y, Doi A, Sato K, Sakane S, Makino Y, Kodama T, Sakamori R, Tatsumi T, Takehara T.
    Hepatol Commun. 2021 Sep 28. Online ahead of print.
28. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.
    Tokushige K, Ikejima K, Ono M, Eguchi Y, Kamada Y, Itoh Y, Akuta N, Yoneda M, Iwasa M, Yoneda M, Otsuka M, Tamaki N, Kogiso T, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K.
    J Gastroenterol. 2021 Sep 17. Online ahead of print.
29. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.
    Tokushige K, Ikejima K, Ono M, Eguchi Y, Kamada Y, Itoh Y, Akuta N, Yoneda M, Iwasa M, Yoneda M, Otsuka M, Tamaki N, Kogiso T, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K.
    Hepatol Res. 2021 Oct;51(10):1013-1025
30. Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals.
    Tahata Y, Sakamori R, Yamada R, Kodama T, Hikita H, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Oshita M, Ohkawa K, Hijioka T, Fukui H, Ito T, Doi Y, Yamada Y, Yakushijin T, Yoshida Y, Tatsumi T, Takehara T; Osaka Liver Forum.
    Aliment Pharmacol Ther. 2021 Oct. Online ahead of print
31. Hepatocellular carcinoma in a patient with tetralogy of Fallot: A case report and literature review.
    Ji Hyun Sung, Ryotaro Sakamori, Ryoko Yamada, Teppei Yoshioka, Sadatsugu Sakane, Yuki Tahata, Minoru Shigekawa, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara.
    Internal Medicine. 2021 (in press)
32. Serum growth differentiation factor 15 predicts　hepatocellular carcinoma occurrence after　hepatitis C virus　elimination.
    Yuta Myojin, Hayato Hikita, Yuki Tahata, Akira Doi, Seiya Kato, Yoichi, Sasaki, Kumiko Shirai, Sadatsugu Sakane, Ryoko Yamada, Takahiro Kodama, Hideki Hagiwara, Yasuharu Imai, Naoki Hiramatsu, Shinji Tamura, Keiji, Yamamoto, Kazuyoshi Ohkawa, Taizo Hijioka, Hiroyuki Fukui, Yoshinori Doi, Yukinori Yamada, Takayuki Yakushijin, Eiji Mita, Ryotaro Sakamori, Tomohide Tatsumi, Tetsuo Takehara.
    Alimentary Pharmacology & Therapeutics　2021(in press)
33. Treatment progress and expansion in Japan: From interferon to direct-acting antiviral.
    Tahata Y, Sakamori R, Takehara T.
    Glob Health Med. 2021 Oct 31;3(5):321-334.
    
34. Rebleeding in patients with delayed bleeding after endoscopic submucosal dissection for early gastric cancer.
    Hashimoto M, Hatta W, Tsuji Y, Yoshio T, Yabuuchi Y, Hoteya S, Doyama H, Nagami Y, Hikichi T, Kobayashi M, Morita Y, Sumiyoshi T, Iguchi M, Tomida H, Inoue T, Mikami T, Hasatani K, Nishikawa J, Matsumura T, Nebiki H, Nakamatsu D, Ohnita K, Suzuki H, Ueyama H, Hayashi Y, Sugimoto M, Fujishiro M, Masamune A, Ohira H; Collaborators.
    Dig Endosc. 2021 Nov;33(7):1120-1130.
    
35. Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.
    Kozumi K, Kodama T, Murai H, Sakane S, Govaere O, Cockell S, Motooka D, Kakita N, Yamada Y, Kondo Y, Tahata Y, Yamada R, Hikita H, Sakamori R, Kamada Y, Daly AK, Anstee QM, Tatsumi T, Morii E, Takehara T.
    Hepatology. 2021 Nov;74(5):2452-2466
    
36. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.
    Tokushige K, Ikejima K, Ono M, Eguchi Y, Kamada Y, Itoh Y, Akuta N, Yoneda M, Iwasa M, Yoneda M, Otsuka M, Tamaki N, Kogiso T, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K.
    J Gastroenterol. 2021 Nov;56(11):951-963.
    
37. Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals.
    Tahata Y, Sakamori R, Yamada R, Kodama T, Hikita H, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Oshita M, Ohkawa K, Hijioka T, Fukui H, Ito T, Doi Y, Yamada Y, Yakushijin T, Yoshida Y, Tatsumi T, Takehara T; Osaka Liver Forum.
    Aliment Pharmacol Ther. 2021 Nov;54(10):1340-1349.
    
38. White Adipose Tissue Autophagy and Adipose-Liver Crosstalk Exacerbate Nonalcoholic Fatty Liver Disease in Mice.
    Sakane S, Hikita H, Shirai K, Myojin Y, Sasaki Y, Kudo S, Fukumoto K, Mizutani N, Tahata Y, Makino Y, Yamada R, Kodama T, Sakamori R, Tatsumi T, Takehara T.
    Cell Mol Gastroenterol Hepatol. 2021;12(5):1683-1699.
    

邦論文

1. IBDの診断方法と病勢評価法をGLから読み解く―バイオマーカーを含めて―
   新﨑信一郎、飯島　英樹、竹原　徹郎
   日本消化器病学会雑誌2021年118巻7号 p.598-606
2. NAFLDをめぐる諸問題〜NASH病理診断の変遷に付随する問題点から病名変更の混乱まで〜
   小玉　尚宏、木積　一浩、竹原　徹郎
   肝臓 2021

患者の皆様へ

学生・研修医のみなさまへ

阪大消化器内科のご紹介